Understanding peptide saturation & steady state

Science 6 min read Reviewed

The core pharmacokinetic concept behind every protocol. What steady state is, the 5-half-life rule, and why it is the single most important metric for understanding whether your protocol is working.

Contents7
  1. 1The 5-half-life rule
  2. 2Real-world examples
  3. 3Why saturation matters
  4. 4Saturation and multi-compound stacks
  5. 5What saturation is and is not
  6. 6Visualizing your saturation
  7. 7References

An injected compound follows a pharmacokinetic lifecycle: it absorbs into the bloodstream, reaches a peak concentration, distributes through tissues, and is gradually eliminated by the body. The rate of elimination is described by the compound's half-life, the time required for its concentration to decrease to half.1

After a single dose, the compound clears. With repeated doses on a schedule, each new dose adds to whatever remains from previous doses. The blood concentration does not start from zero each time. It builds.

The point where this buildup stabilizes, where the amount being added by each new dose equals the amount being cleared, is called steady state. At steady state, blood levels follow a consistent cycle of peak and trough that repeats with each dosing interval.

The 5-half-life rule

Most clinically relevant drugs follow first-order pharmacokinetics: the rate of elimination is proportional to concentration, so 50% is removed in each half-life.1 Under that model, regular dosing approaches steady state by a fixed fraction per half-life, and 5 half-lives brings it to about 97%. The figures below are that arithmetic: 1 minus one half raised to the number of half-lives.

The share of steady state reached after each half-life of consistent dosing:

Saturation buildup over time

1 half-life
50%
2 half-lives
75%
3 half-lives
87.5%
4 half-lives
93.8%
5 half-lives
96.9%

At 5 half-lives, levels are at about 97% of the eventual steady-state concentration, and further doses add little more buildup.

The labels bear this out. Semaglutide has an elimination half-life of approximately 1 week and reaches steady state after 4 to 5 weeks of once-weekly doses; tirzepatide, approximately 5 days, after 4 weeks.23 What changes between compounds is the half-life, which sets how long each step takes in real time.

Real-world examples

Plugging in published half-lives shows how widely the time to steady state varies.

BPC-157

t½ < 30 min (animals)
Half-Life
< 30 min
5 Half-Lives
< 2.5 hrs
Steady State
Same Day

In rats and beagle dogs, the elimination half-life of BPC-157 was less than 30 minutes.4 No human pharmacokinetic data was found. On that half-life, each daily dose would be almost entirely cleared before the next, so BPC-157 would not meaningfully accumulate: each dose is a brief spike followed by clearance.

Testosterone enanthate

Weekly, by label
Half-Life
Not on label
5 Half-Lives
n/a
Steady State
By week 6

The Xyosted label (weekly testosterone enanthate under the skin) gives no half-life, but reports that steady state serum testosterone was achieved by week 6, and it bases the first dose adjustment on a trough level measured after 6 weeks of dosing.5 That is the point where bloodwork reflects the regular schedule rather than the ramp-up. For comparison, the Depo-Testosterone label gives testosterone cypionate a half-life of approximately eight days.6

Semaglutide

t½ ≈ 1 week
Half-Life
~7 days
5 Half-Lives
35 days
Steady State
4 to 5 weeks

Semaglutide's label gives an elimination half-life of approximately 1 week and steady state after 4 to 5 weeks of once-weekly doses, so each injection adds to residual levels from previous weeks.2 The Wegovy label starts at 0.25 mg once weekly for 4 weeks and titrates every 4 weeks to the maintenance dose.7

Why saturation matters

Where levels sit on the saturation curve bears on a common question in the first weeks of a protocol: "is it working?"

At 45% saturation, blood levels have not yet reached the concentration the schedule will settle at. Reading week-12 results into a 45% point is like expecting to be at the top of a staircase on step 5 of 10.

Past 90% saturation, each dose mostly maintains levels rather than building them further. This is the maintenance phase.

The practical implication

Under first-order kinetics, raising the dose at 50% saturation does not speed up reaching steady state at the original dose; it starts the climb toward a new, higher steady state, which again takes about 5 half-lives.

Saturation and multi-compound stacks

When running a multi-compound stack, each compound in the stack saturates independently. A stack of BPC-157 (half-life under 30 minutes in animal studies) and weekly testosterone enanthate (steady state by week 6 on its label) has one compound at steady state within hours while the other is still building.45

Short half-life compounds are at steady state within days while long half-life compounds are still climbing. Knowing which compounds in a stack are saturated and which are still building gives context for what is felt, or not felt, at any given point.

What saturation is and is not

A few clarifications that help frame this concept correctly:

  • Saturation is not a measure of effectiveness. It is a measure of blood level stability. A compound at 100% saturation is not "more effective" than at 80%; it means the peak-trough cycle has fully stabilized.
  • Saturation is dose-independent. Under first-order kinetics, whether the dose is 100mg or 500mg per week, steady state still takes about 5 half-lives; the semaglutide label, for example, reports exposure rising in proportion to dose.2 The dose determines the eventual blood level; the half-life determines how long it takes to get there.
  • Saturation falls if doses are missed. Consistent dosing is what drives accumulation. Missing doses during the ramp-up period extends the time to steady state. Missing doses after reaching steady state causes levels to decay according to the half-life.
  • Saturation assumes consistent dosing intervals. Irregular spacing between doses produces irregular blood levels. The 5 half-life figure applies cleanly when doses are evenly spaced at the same interval.

Visualizing your saturation

The saturation curve, a graph of blood concentration over time as doses accumulate toward steady state, shows where levels are in the buildup, when you will reach stable levels, and what the peak-to-trough variation looks like at different points in the protocol.

For long-acting compounds, the curve is a gradually rising staircase where each step is a dose. For short-acting compounds, the curve looks like a series of spikes with minimal carry-over. For intermediate compounds, it is a rising wave that progressively dampens into a stable oscillation.

This is the pharmacokinetic curve that Milligram generates in real time for every compound in your protocol. It takes the abstract concept of steady state and turns it into a concrete, visual answer to "where am I right now?"

References

  1. Hallare J, Gerriets V. Elimination half-life of drugs. StatPearls (NCBI Bookshelf, PubMed record). 2025. pubmed.ncbi.nlm.nih.gov
  2. Novo Nordisk (DailyMed). Ozempic (semaglutide) injection label. 2026. dailymed.nlm.nih.gov
  3. Eli Lilly (DailyMed). Mounjaro (tirzepatide) injection label. 2026. dailymed.nlm.nih.gov
  4. He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022. pubmed.ncbi.nlm.nih.gov
  5. Antares Pharma (DailyMed). Xyosted (testosterone enanthate) injection label. 2026. dailymed.nlm.nih.gov
  6. Pharmacia & Upjohn (DailyMed). Depo-Testosterone (testosterone cypionate) injection label. 2026. dailymed.nlm.nih.gov
  7. Novo Nordisk (DailyMed). Wegovy (semaglutide) label. 2026. dailymed.nlm.nih.gov